We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Evaluating the Bioavailability of Naproxen 500 mg in Three Formulations

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00665743
First Posted: April 24, 2008
Last Update Posted: June 10, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
POZEN
April 23, 2008
April 24, 2008
June 10, 2008
March 2008
June 2008   (Final data collection date for primary outcome measure)
To assess and compare the pharmacokinetics and relative bioavailability of a single oral dose of naproxen 500 mg administered in 3 formulations [ Time Frame: 72-hour PK ]
Same as current
Complete list of historical versions of study NCT00665743 on ClinicalTrials.gov Archive Site
To evaluate the safety of the 3 treatments [ Time Frame: entire study duration ]
Same as current
Not Provided
Not Provided
 
Study Evaluating the Bioavailability of Naproxen 500 mg in Three Formulations
An Open-Label, Randomized, 3-Way Crossover Study to Evaluate the Relative Bioavailability of a Single Oral Dose of Naproxen 500 mg Administered as PN 400 (Naproxen / Esomeprazole), as the [Active Comparator 1], or as [Active Comparator 2] in Healthy Volunteers
We will evaluate the bioavailability of naproxen 500 mg administered as three dfferent formulations.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Arthritis
  • Drug: PN400
    naproxen 500 mg /esomeprazole 20 mg
  • Drug: naproxen
    naproxen 500 mg tablet
  • Drug: naproxen
    naproxen 500 mg
  • Experimental: A
    PN400 (naproxen/esomeprazole)
    Intervention: Drug: PN400
  • Active Comparator: B
    naproxen 500 mg
    Intervention: Drug: naproxen
  • Active Comparator: C
    naproxen 500 mg
    Intervention: Drug: naproxen
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
June 2008
June 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy male or non-pregnant female subjects between 18-55 years of age as well as other standard inclusion criteria for a study of this nature

Exclusion Criteria:

  • Standard exclusion criteria for a study of this nature
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00665743
PN400-102
No
Not Provided
Not Provided
David Taylor, Pozen
POZEN
Not Provided
Not Provided
POZEN
June 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP
To Top